Key result
The novel oral polio vaccine type 2 (nOPV2) was the first vaccine to receive a WHO Emergency Use Listing (EUL), establishing a pathway for accelerated vaccine roll-out during public health emergencies.
Why the study?
To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2) by deploying novel oral polio vaccine type 2 under Emergency Use Listing.
This report summarizes the regulatory and rollout pathway for nOPV2 under the WHO's Emergency Use Listing, which set a precedent for future emergency vaccines.
No takes yet. Share an insight, caveat, or question.
Supports expedited emergency vaccine pathways; leaves open long-term safety and efficacy validation for future EUL candidates.
Macklin et al. (2022) conducted a review in circulating vaccine-derived poliovirus type 2 (cVDPV2). novel oral polio vaccine type 2 (nOPV2) was evaluated. The novel oral polio vaccine type 2 (nOPV2) was the first vaccine to receive a WHO Emergency Use Listing (EUL), establishing a pathway for accelerated vaccine roll-out during public health emergencies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: